MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585110 | Name: Tramazoline HCl hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tramazoline is an imidazoline derivative that acts as a selective α1 adrenergic receptor agonist, primarily used as a topical nasal decongestant. Its pharmacological activity stems from vasoconstriction of nasal mucosal blood vessels, leading to reduced edema and improved airflow. In vitro studies show tramazoline has high affinity for α1A α 1D receptors (Ki values in the low nanomolar range), while demonstrating negligible activity at β-adrenergic or central nervous system receptors, minimizing systemic side effects. In vivo, intranasal administration in humans produces rapid onset of decongestion (within 5–10 minutes) with effects lasting 6–8 hours.

Chemical Structure

Tramazoline HCl hydrate
Tramazoline HCl hydrate
CAS#74195-73-6 (HCl hydrate)

Theoretical Analysis

MedKoo Cat#: 585110

Name: Tramazoline HCl hydrate

CAS#: 74195-73-6 (HCl hydrate)

Chemical Formula: C13H20ClN3O

Exact Mass: 215.1422

Molecular Weight: 269.77

Elemental Analysis: C, 57.88; H, 7.47; Cl, 13.14; N, 15.58; O, 5.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1082-57-1 (free base) 3715-90-0 (HCl) 74195-73-6 (HCl hydrate)
Synonym
Tramazoline; Rhinol; Rhynaspray; Tobispray
IUPAC/Chemical Name
4,5-Dihydro-N-(5,6,7,8-tetrahydro-1-naphthalenyl)-1H-imidazol-2-amine hydrochloride hydrate
InChi Key
FDPYEAXJRLQOGE-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H17N3.ClH.H2O/c1-2-6-11-10(4-1)5-3-7-12(11)16-13-14-8-9-15-13;;/h3,5,7H,1-2,4,6,8-9H2,(H2,14,15,16);1H;1H2
SMILES Code
[H]Cl.[H]O[H].C1(NC2=C3CCCCC3=CC=C2)=NCCN1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 269.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gaisl T, Haile SR, Thiel S, Osswald M, Kohler M. Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis. Sleep Med Rev. 2019 Aug;46:74-86. doi: 10.1016/j.smrv.2019.04.009. Epub 2019 Apr 19. Review. PubMed PMID: 31075665. 2: Wieneke H. Induction of Atrial Fibrillation by Topical Use of Nasal Decongestants. Mayo Clin Proc. 2016 Jul;91(7):977. doi: 10.1016/j.mayocp.2016.04.011. PubMed PMID: 27378046. 3: Katona G, Sultész M, Farkas Z, Gyimesi A, Hirschberg A, Huszka J, Radvánszky F, Simon Á, Fülöp G, Láng J, Ablonczy M, Nirnberger G, Holm C. Treatment of acute rhinitis with a nasal spray containing tramazoline and essential oils: a multicenter, uncontrolled, observational trial. Clin Transl Allergy. 2015 Nov 4;5:38. doi: 10.1186/s13601-015-0084-5. eCollection 2015. PubMed PMID: 26539289; PubMed Central PMCID: PMC4632331. 4: Koutsourelakis I, Minaritzoglou A, Zakynthinos G, Vagiakis E, Zakynthinos S. The effect of nasal tramazoline with dexamethasone in obstructive sleep apnoea patients. Eur Respir J. 2013 Oct;42(4):1055-63. doi: 10.1183/09031936.00142312. Epub 2013 Feb 8. PubMed PMID: 23397296. 5: Antoniou CG, Markopoulou CK, Kouskoura MG, Koundourellis JE. Study and development of reversed-phase HPLC systems for the determination of 2-imidazolines in the presence of preservatives in pharmaceutical preparations. J AOAC Int. 2011 May-Jun;94(3):703-12. PubMed PMID: 21796997. 6: Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, Mela EK, Goumas PD, Gartaganis SP. The effect of nasal steroid administration on intraocular pressure. Ear Nose Throat J. 2007 Jul;86(7):394-5. PubMed PMID: 17702318. 7: Finsterer J, Fröhlinger W. Tramazoline turns asymptomatic into symptomatic hyper-CK-emia. Eur J Neurol. 2007 Mar;14(3):e7. PubMed PMID: 17355540. 8: Sichletidis L, Chloros D, Tsiotsios I, Gioulekas D, Kyriazis G, Spyratos D, Charalambidou O, Goutsikas S. The prevalence of allergic asthma and rhinitis in children of Polichni, Thessaloniki. Allergol Immunopathol (Madr). 2004 Mar-Apr;32(2):59-63. PubMed PMID: 15087091. 9: Verse T, Sikora C, Rudolph P, Klöcker N. [The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters]. Laryngorhinootologie. 2003 Nov;82(11):782-9. German. PubMed PMID: 14634896. 10: Hayasaka Y, Hayasaka S, Zhang XY, Nagaki Y. Effects of topical mydriatics and vasoconstrictors on prostaglandin-E2-induced aqueous flare elevation in pigmented rabbits. Ophthalmic Res. 2003 Sep-Oct;35(5):256-60. PubMed PMID: 12920338. 11: Hochban W, Althoff H, Ziegler A. Nasal decongestion with imidazoline derivatives: acoustic rhinometry measurements. Eur J Clin Pharmacol. 1999 Mar;55(1):7-12. PubMed PMID: 10206078. 12: González-Peñas E, Aldana I, Esteras A, Bruseghini L, Gazzaniga A, Gianesello W. Absorption of sodium diclofenac after ocular administration in rabbit. Arzneimittelforschung. 1998 Sep;48(9):931-4. PubMed PMID: 9793621. 13: Takeno S, Kawamoto H, Hirata S, Fukushima N, Yazin K. [Decongesting effect of tramazoline on nasal airway patency and nasal symptoms as evaluated by acoustic rhinometry: an objective study in 30 allergic and six non-allergic subjects]. Nihon Jibiinkoka Gakkai Kaiho. 1998 Jul;101(7):900-7. Japanese. PubMed PMID: 9745265. 14: Yamagiwa M. Acoustic evaluation of the efficacy of medical therapy for allergic nasal obstruction. Eur Arch Otorhinolaryngol. 1997;254 Suppl 1:S82-4. PubMed PMID: 9065635. 15: Schött D, Ulmer WT. [Clinical investigation of the action of tramazoline inpatients with chronic obstructive bronchitis. The importance of mucosal swelling]. Arzneimittelforschung. 1996 Dec;46(12):1127-30. German. PubMed PMID: 9065316. 16: Peng N, Meng QC, King K, Oparil S, Wyss JM. Acute hypertension increases norepinephrine release in the anterior hypothalamic area. Hypertension. 1995 Apr;25(4 Pt 2):828-33. PubMed PMID: 7721439. 17: Sakuta H, Okamoto K. Inhibition by imidazoline and imidazolidine derivatives of glibenclamide-sensitive K+ currents in Xenopus oocytes. Eur J Pharmacol. 1994 Jul 11;259(3):223-31. PubMed PMID: 7982448. 18: Berger ME, Golub MS, Chang CT, al-Kharouf JA, Nyby MD, Hori M, Brickman AS, Tuck ML. Flavonoid potentiation of contractile responses in rat blood vessels. J Pharmacol Exp Ther. 1992 Oct;263(1):78-83. PubMed PMID: 1403805. 19: Pi F, García-Sevilla JA. Alpha 2-autoreceptor-mediated modulation of tyrosine hydroxylase activity in noradrenergic regions of the rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):653-60. PubMed PMID: 1353254. 20: Hikasa Y, Ogasawara S, Takase K. Alpha adrenoceptor subtypes involved in the emetic action in dogs. J Pharmacol Exp Ther. 1992 May;261(2):746-54. PubMed PMID: 1349647.